Literature DB >> 20731579

Update and overview of outpatient parenteral antimicrobial therapy regulations and reimbursement.

Barbara Ross Nolet1.   

Abstract

Outpatient care, including outpatient parenteral antimicrobial therapy (OPAT), is increasingly seen by both clinicians and insurers as a safe, effective, and economical adjunct or alternative to hospitalization. Despite this, perhaps the least understood reimbursement and regulatory policies for health care services are those that apply to OPAT. We present a brief review and update of current rules and regulations relating to OPAT, with emphasis on areas of special interest to physicians serving as medical directors of home or ambulatory infusion programs or providing OPAT as an extension of their office practices.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20731579     DOI: 10.1086/653522

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

1.  Outpatient parenteral antibiotic therapy (OPAT) at home in Attica, Greece.

Authors:  G Theocharis; P I Rafailidis; D Rodis; I Kontopidis; S G Barbas; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-02       Impact factor: 3.267

2.  Are we ready for an outpatient parenteral antimicrobial therapy bundle? A critical appraisal of the evidence.

Authors:  Eavan G Muldoon; David R Snydman; Elizabeth C Penland; Geneve M Allison
Journal:  Clin Infect Dis       Date:  2013-04-09       Impact factor: 9.079

3.  Predictors of Unplanned Hospitalization in Patients Receiving Outpatient Parenteral Antimicrobial Therapy Across a Large Integrated Healthcare Network.

Authors:  Monica Schmidt; Bevin Hearn; Michael Gabriel; Melanie D Spencer; Lewis McCurdy
Journal:  Open Forum Infect Dis       Date:  2017-06-16       Impact factor: 3.835

4.  Perspectives of United States-based Infectious Diseases Physicians on Outpatient Parenteral Antimicrobial Therapy Practice.

Authors:  Yasir Hamad; Michael A Lane; Susan E Beekmann; Philip M Polgreen; Sara C Keller
Journal:  Open Forum Infect Dis       Date:  2019-10-01       Impact factor: 3.835

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.